208 related articles for article (PubMed ID: 33821666)
1. Review of the rechargeable sacral neuromodulation system to treat refractory overactive bladder.
Albabtain M; Chughtai B; Cho A; Elterman D
Ther Deliv; 2021 May; 12(5):353-362. PubMed ID: 33821666
[TBL] [Abstract][Full Text] [Related]
2. Axonics® system for treatment of overactive bladder syndrome and urinary urgency incontinence.
Wang A; Rourke E; Sebesta E; Dmochowski R
Expert Rev Med Devices; 2021 Aug; 18(8):727-732. PubMed ID: 34187274
[No Abstract] [Full Text] [Related]
3. Sacral neuromodulation system for treating refractory overactive bladder.
Phillips A
Br J Nurs; 2020 Oct; 29(18):S30-S37. PubMed ID: 33035097
[TBL] [Abstract][Full Text] [Related]
4. Two-year safety and efficacy outcomes for the treatment of overactive bladder using a long-lived rechargeable sacral neuromodulation system.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Perrouin-Verbe MA; Elneil S
Neurourol Urodyn; 2020 Apr; 39(4):1108-1114. PubMed ID: 32243625
[TBL] [Abstract][Full Text] [Related]
5. Three month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe M; Elneil S
Neurourol Urodyn; 2018 Feb; 37(S2):S9-S16. PubMed ID: 29315785
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Urinary Urgency Incontinence Using a Rechargeable SNM System: 6-Month Results of the ARTISAN-SNM Study.
McCrery R; Lane F; Benson K; Taylor C; Padron O; Blok B; De Wachter S; Pezzella A; Gruenenfelder J; Pakzad M; Perrouin-Verbe MA; Le Normand L; Van Kerrebroeck P; Mangel J; Peters K; Kennelly M; Shapiro A; Lee U; Comiter C; Mueller M; Goldman HB
J Urol; 2020 Jan; 203(1):185-192. PubMed ID: 31347955
[TBL] [Abstract][Full Text] [Related]
7. Axonics Sacral Neuromodulation System for Treating Refractory Overactive Bladder: A NICE Medical Technologies Guidance.
Poole RL; Dale M; Morgan H; Oladapo T; Brookfield R; Morris R
Appl Health Econ Health Policy; 2022 May; 20(3):305-313. PubMed ID: 34964090
[TBL] [Abstract][Full Text] [Related]
8. The novel Axonics® rechargeable sacral neuromodulation system: Procedural and technical impressions from an initial North American experience.
Elterman DS
Neurourol Urodyn; 2018 Feb; 37(S2):S1-S8. PubMed ID: 29336078
[TBL] [Abstract][Full Text] [Related]
9. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe MA; Elneil S
Neurourol Urodyn; 2019 Feb; 38(2):689-695. PubMed ID: 30592526
[TBL] [Abstract][Full Text] [Related]
10. Unilateral versus bilateral sacral neuromodulation test in the treatment of refractory idiopathic overactive bladder: A randomized controlled pilot trial.
Wagner L; Alonso S; Le Normand L; Faix A; Kabani S; Castelli C; Gamé X; Cornu JN; Bey E
Neurourol Urodyn; 2020 Nov; 39(8):2230-2237. PubMed ID: 32835443
[TBL] [Abstract][Full Text] [Related]
11. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
[TBL] [Abstract][Full Text] [Related]
12. Two-year outcomes of the ARTISAN-SNM study for the treatment of urinary urgency incontinence using the Axonics rechargeable sacral neuromodulation system.
Pezzella A; McCrery R; Lane F; Benson K; Taylor C; Padron O; Blok B; de Wachter S; Gruenenfelder J; Pakzad M; Perrouin-Verbe MA; van Kerrebroeck P; Mangel J; Peters K; Kennelly M; Shapiro A; Lee U; Comiter C; Mueller M; Goldman HB
Neurourol Urodyn; 2021 Feb; 40(2):714-721. PubMed ID: 33508155
[TBL] [Abstract][Full Text] [Related]
13. Cost profiles and budget impact of rechargeable versus non-rechargeable sacral neuromodulation devices in the treatment of overactive bladder syndrome.
Noblett KL; Dmochowski RR; Vasavada SP; Garner AM; Liu S; Pietzsch JB
Neurourol Urodyn; 2017 Mar; 36(3):727-733. PubMed ID: 27062384
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the axonics modulation technologies sacral neuromodulation system for the treatment of urinary and fecal dysfunction.
Cohn JA; Kowalik CG; Kaufman MR; Reynolds WS; Milam DF; Dmochowski RR
Expert Rev Med Devices; 2017 Jan; 14(1):3-14. PubMed ID: 27915486
[TBL] [Abstract][Full Text] [Related]
15. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation.
Siegel S; Noblett K; Mangel J; Bennett J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Zylstra S; Kan F; Berg KC
J Urol; 2018 Jan; 199(1):229-236. PubMed ID: 28709886
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of sacral neuromodulation on urological diseases: a multicentric research project.
Cardarelli S; D'Elia C; Cerruto MA; Curti P; Ostardo E; Signorello D; Pastorello M; Caleffi G; Molon A; Artibani W
Urologia; 2012; 79(2):90-6. PubMed ID: 22610844
[TBL] [Abstract][Full Text] [Related]
17. Do Patients Discontinue Overactive Bladder Medications after Sacral Neuromodulation?
Amin K; Moskowitz D; Kobashi KC; Lee UJ; Lucioni A
J Urol; 2019 May; 201(5):973-978. PubMed ID: 30694936
[TBL] [Abstract][Full Text] [Related]
18. Programming settings and recharge interval in a prospective study of a rechargeable sacral neuromodulation system for the treatment of overactive bladder.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe M; Elneil S
Neurourol Urodyn; 2018 Feb; 37(S2):S17-S22. PubMed ID: 29336058
[TBL] [Abstract][Full Text] [Related]
19. Sacral neuromodulation for refractory overactive bladder, interstitial cystitis, and painful bladder syndrome.
Laviana A; Jellison F; Kim JH
Neurosurg Clin N Am; 2014 Jan; 25(1):33-46. PubMed ID: 24262898
[TBL] [Abstract][Full Text] [Related]
20. Increasing patient preparedness for sacral neuromodulation improves patient reported outcomes despite leaving objective measures of success unchanged.
Firoozi F; Gill B; Ingber MS; Moore CK; Rackley RR; Goldman HB; Vasavada SP
J Urol; 2013 Aug; 190(2):594-7. PubMed ID: 23499745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]